Table: Santen Pharm -6-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

07/11/2018 06:00

Nov 7 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Sep 30, 2018        Sep 30, 2017     Mar 31, 2019 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              114.34              110.77           237.00    
                   (+3.2 pct)          (+13.2 pct)      (+5.4 pct)  
  Operating           20.83               21.04            40.70    
                   (-1.0 pct)          (+12.0 pct)      (+5.2 pct)  
  Pretax              19.79               20.69            41.30    
                   (-4.3 pct)          (+22.5 pct)      (+5.2 pct)  
  Net                 14.38               15.26                     
                   (-5.7 pct)          (+22.0 pct)                  
  EPS Basic         35.34 yen           37.56 yen        75.21 yen  
  EPS Diluted       35.23 yen           37.42 yen                   
  Ann Div                               26.00 yen        26.00 yen  
  -Q2 Div           13.00 yen           13.00 yen                   
  -Q4 Div                               13.00 yen        13.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T